How Immunocompromised Hosts Were Left Behind in the Quest to Control the COVID-19 Pandemic

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2024 Jun 3

PMID 38825885

Authors

Michael Boeckh

Steven A Pergam

Ajit P Limaye

Janet Englund

Lawrence Corey

Joshua A Hill

Affiliations

Soon will be listed here.

Abstract

The immunocompromised population was disproportionately affected by the severe acute respiratory syndrome coronavirus 2 pandemic. However, these individuals were largely excluded from clinical trials of vaccines, monoclonal antibodies, and small molecule antivirals. Although the community of scientists, clinical researchers, and funding agencies have proven that these therapeutics can be made and tested in record time, extending this progress to vulnerable and medically complex individuals from the start has been a missed opportunity. Here, we advocate that it is paramount to plan for future pandemics by investing in specific clinical trial infrastructure for the immunocompromised population to be prepared when the need arises.

Citing Articles

New approach methodologies to assess wanted and unwanted drugs-induced immunostimulation.

Bettinsoli V, Melzi G, Marchese I, Pantaleoni S, Passoni F, Corsini E Curr Res Toxicol. 2025; 8:100222.

PMID: 40027547 PMC: 11872130. DOI: 10.1016/j.crtox.2025.100222.

Remdesivir Effectiveness in Reducing the Risk of 30-Day Readmission in Vulnerable Patients Hospitalized for COVID-19: A Retrospective US Cohort Study Using Propensity Scores.

Mozaffari E, Chandak A, Gottlieb R, Kalil A, Jiang H, Oppelt T Clin Infect Dis. 2024; 79(Supplement_4):S167-S177.

PMID: 39405450 PMC: 11638780. DOI: 10.1093/cid/ciae511.

Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era.

Mozaffari E, Chandak A, Gottlieb R, Chima-Melton C, Berry M, Amin A Clin Infect Dis. 2024; 79(Supplement_4):S149-S159.

PMID: 39405443 PMC: 11638779. DOI: 10.1093/cid/ciae510.

Bridging the Gap: Delphi Consensus Statements for SARS-CoV-2 Vaccination in Immunocompromised Patients.

Ravkin H, Nesher L Infect Dis Ther. 2024; 13(11):2223-2225.

PMID: 39387988 PMC: 11499500. DOI: 10.1007/s40121-024-01049-3.

Does early combination vs. Monotherapy improve clinical outcomes of clinically extremely vulnerable patients with COVID-19? Results from a retrospective propensity-weighted analysis.

Maria M, Maraolo A, Cozzolino C, Sasset L, Ferrari A, Basso M Eur J Med Res. 2024; 29(1):484.

PMID: 39367485 PMC: 11451216. DOI: 10.1186/s40001-024-02062-5.

References

Khawaja F, Papanicolaou G, Dadwal S, Pergam S, Wingard J, Boghdadly Z . Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of.... Transplant Cell Ther. 2022; 29(1):10-18. PMC: 9584756. DOI: 10.1016/j.jtct.2022.10.010. View

Patel M, Chen J, Kim S, Garg S, Flannery B, Haddadin Z . Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States. Emerg Infect Dis. 2020; 26(8):1720-1730. PMC: 7392442. DOI: 10.3201/eid2608.191493. View

Meiring S, Tempia S, Bhiman J, Buys A, Kleynhans J, Makhasi M . Prolonged Shedding of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at High Viral Loads Among Hospitalized Immunocompromised Persons Living With Human Immunodeficiency Virus (HIV), South Africa. Clin Infect Dis. 2022; 75(1):e144-e156. PMC: 8903337. DOI: 10.1093/cid/ciac077. View

Wang L, Verschuuren E, Van Leer-Buter C, Bakker S, de Joode A, Westra J . Herpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the Literature. Front Immunol. 2018; 9:1632. PMC: 6062765. DOI: 10.3389/fimmu.2018.01632. View

Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Al Zahrani M . COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021; 35(10):2885-2894. PMC: 8171362. DOI: 10.1038/s41375-021-01302-5. View

Sharma A, Bhatt N, Martin A, Abid M, Bloomquist J, Chemaly R . Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021; 8(3):e185-e193. PMC: 7816949. DOI: 10.1016/S2352-3026(20)30429-4. View

Hu X, Karthigeyan K, Herbek S, Valencia S, Jenks J, Webster H . Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine. J Infect Dis. 2024; 230(2):455-466. PMC: 11326847. DOI: 10.1093/infdis/jiad593. View

DeWolf S, Laracy J, Perales M, Kamboj M, van den Brink M, Vardhana S . SARS-CoV-2 in immunocompromised individuals. Immunity. 2022; 55(10):1779-1798. PMC: 9468314. DOI: 10.1016/j.immuni.2022.09.006. View

Cowan J, Amson A, Christofides A, Chagla Z . Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations. Int J Infect Dis. 2023; 134:228-238. DOI: 10.1016/j.ijid.2023.06.021. View

10.

Drzymalla E, Green R, Knuth M, Khoury M, Dotson W, Gundlapalli A . COVID-19-related health outcomes in people with primary immunodeficiency: A systematic review. Clin Immunol. 2022; 243:109097. PMC: 9375253. DOI: 10.1016/j.clim.2022.109097. View

11.

Otto S, Day T, Arino J, Colijn C, Dushoff J, Li M . The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. Curr Biol. 2021; 31(14):R918-R929. PMC: 8220957. DOI: 10.1016/j.cub.2021.06.049. View

12.

See K . Vaccination for the Prevention of Infection among Immunocompromised Patients: A Concise Review of Recent Systematic Reviews. Vaccines (Basel). 2022; 10(5). PMC: 9144891. DOI: 10.3390/vaccines10050800. View

13.

Nguyen T, Rowntree L, Allen L, Chua B, Kedzierski L, Lim C . Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells. Cell Rep Med. 2023; 4(4):101017. PMC: 10040362. DOI: 10.1016/j.xcrm.2023.101017. View

14.

Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci D . Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2022; 327(13):1236-1246. PMC: 8922199. DOI: 10.1001/jama.2022.2832. View

15.

Meejun T, Srisurapanont K, Manothummetha K, Thongkam A, Mejun N, Chuleerarux N . Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis. Blood Adv. 2023; 7(18):5624-5636. PMC: 10514108. DOI: 10.1182/bloodadvances.2023010349. View

16.

Meijer S, Halutz O, Adler A, Levytskyi K, Tau L, Dekel M . Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects. J Infect Chemother. 2023; 30(3):271-275. DOI: 10.1016/j.jiac.2023.10.022. View

17.

Mena Lora A, Long J, Huang Y, Baden L, El Sahly H, Follmann D . Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. JAMA Netw Open. 2023; 6(1):e2251974. PMC: 10546713. DOI: 10.1001/jamanetworkopen.2022.51974. View

18.

Ogimi C, Xie H, Waghmare A, Jerome K, Leisenring W, Milano F . Correlation of initial upper respiratory tract viral burden with progression to lower tract disease in adult allogeneic hematopoietic cell transplant recipients. J Clin Virol. 2022; 150-151:105152. PMC: 9206235. DOI: 10.1016/j.jcv.2022.105152. View

19.

Schilling W, Jittamala P, Watson J, Boyd S, Luvira V, Siripoon T . Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial. Lancet Infect Dis. 2023; 24(1):36-45. PMC: 7615401. DOI: 10.1016/S1473-3099(23)00493-0. View

20.

Huisman W, Martina B, Rimmelzwaan G, Gruters R, Osterhaus A . Vaccine-induced enhancement of viral infections. Vaccine. 2008; 27(4):505-12. PMC: 7131326. DOI: 10.1016/j.vaccine.2008.10.087. View